Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
Prothena(US:PRTA) Businesswire·2025-10-01 20:45公司动态 - 百时美施贵宝向公司传达美国食品药品监督管理局已授予其在研药物BMS-986446快速通道资格 [1] - 获得快速通道资格的药物BMS-986446是一种抗tau抗体 [1] - BMS-986446目前处于阿尔茨海默病的二期临床试验阶段 [1]